Novo Nordisk, the Danish pharma company behind Ozempic and Wegovy, made one very dumb decision a few years ago that will massively eat into its profits — and honestly, all we can do is laugh. When watching an interview with the head of generic drugmaker Sandoz, Science magazine columnist Derek Lowe learned something incredible: that Novo failed to renew its Canadian patent on semaglutide, the active ingredient in the uber-expensive drugs Ozempic and Wegovy. Speaking to the biopharma industry outlet Endpoints News earlier this month, Sandoz CEO Richard Saynor dropped the information as an aside in a larger conversation about the company's […]